Market-access agreements for anti-cancer drugs

Journal of the Royal Society of Medicine

Volumn 108, Issue 5, 2015, Pages 166-170

  van de Vooren, Katelijne ^a   Curto, Alessandro ^a   Freemantle, Nick ^b   Garattini, Livio ^a  

^a IRCCS Institute for Pharmacological Research Mario Negri   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; AZACITIDINE; BORTEZOMIB; CETUXIMAB; ERLOTINIB; GEFITINIB; IPILIMUMAB; NILOTINIB; PAZOPANIB; SUNITINIB; TRABECTEDIN; VEMURAFENIB;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; GEOGRAPHIC DISTRIBUTION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; KIDNEY CANCER; KIDNEY METASTASIS; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; POLITICAL PARTICIPATION; PROSTATE CANCER; REIMBURSEMENT; SOFT TISSUE SARCOMA; UNITED KINGDOM; CONTRACT; ECONOMICS; ITALY; NEOPLASMS; PUBLIC HEALTH;

ANTINEOPLASTIC AGENTS; CONTRACTS; DRUG INDUSTRY; ENGLAND; HEALTH CARE COSTS; HUMANS; ITALY; NATIONAL HEALTH PROGRAMS; NEOPLASMS; WALES;

EID: 84930464636     PISSN: 01410768     EISSN: 17581095     Source Type: Journal    
DOI: 10.1177/0141076814559626     Document Type: Article

References (20)

1. Garattini S,Bertele V.Efficacy, safety, and cost of new anticancer drugs.BMJ. 2002;325:269-271
2. Carlson JJ,Sullivan SD,Garrison LP,Neumann PJ,Veenstra DL.Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.Health Pol. 2010;96:179-190
3. Garrison LP,Towse A,Briggs A,de Pouvourville G,Grueger J,Mohr P, et al.Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.Value Health. 2013;16:703-719
4. McCabe CJ,Stafinski T,Edlin R,Menon D.Access with evidence development schemes: a framework for description and evaluation.Pharmacoeconomics. 2010;28:143-152
5. Stafinski T,McCabe CJ,Menon D.Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into health care systems.Pharmacoeconomics. 2010;28:113-142
6. Adamski J,Godman B,Ofierska-Sujkowska G,Osińska B,Herholz H,Wendykowska K, et al.Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.BMC Health Serv Res. 2010;10:153-153
7. Garattini L, Curto A and Van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ 2014 [Published online: 12 April 2014].
8. Carlson JJ,Gries KS,Yeung K,Sullivan SD,Garrison LP.Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.Appl Health Econ Health Pol. 2014;12:231-238
9. Agenzia Italiana del Farmaco. Registro Farmaci Oncologici sottoposti a Monitoraggio Rapporto Nazionale 2007. See http://antineoplastici.agenziafarmaco.it/rapporto_RFOM_2007.htm (last checked 27 October 2014).
10. Agenzia Italiana del Farmaco. Lista Aggiornata Dei Nuovi Registri. See http://www.agenziafarmaco.gov.it/it/content/lista-aggiornata-dei-nuovi-registri (last checked 27 October 2014).
11. Garattini L,Casadei G.Risk sharing agreements: what lessons from Italy?.Int J Technol Assess Health Care. 2011;27:169-172
12. Agenzia Italiana del Farmaco. L’uso dei farmaci in Italia. Rapporto nazionale anno 2012. Osservatorio Nazionale sull’impiego dei Medicinali (OsMed). See http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdf (last checked 27 October 2014).
13. Agenzia Italiana del Farmaco. Riunione AIFA – CIPOMO, AIOM, SIFaCT e SIFO. See http://www.sifact.it/joomla/images/pdf/Verbale_Cipomo-Aiom-Sifact-Sifo%20_2.pdf (last checked 27 October 2014).
14. National Institute for Health and Care Excellence (NICE). List of Technologies with Approved Patient Access Schemes, Recommended by Nice for Use in the NHS. See http://www.nice.org.uk/About/What-we-do/Patient-access-schemes-liaison-unit/List-of-technologies-with-approved-Patient-Access-Schemes (last checked 27 October 2014).
15. Department of Health. Pharmaceutical Price Regulation Scheme (PPRS). See https://www.gov.uk/government/publications/pharmaceutical-price-regulation-scheme (last checked 27 October 2014).
16. Spoors J.Patient access schemes in the new NHS.Br J Healthc Manag. 2012;18:412-418
17. British Oncology Pharmacy Association (BOPA). A Report into the Uptake of Patient Access Schemes (PAS) in the NHS. See http://www.bopawebsite.org/contentimages/publications/Report_into_Uptake_of_Patient_Access_Schemes_8_11_09.pdf (last checked 27 October 2014).
18. Haynes S, Timm B, Hamerslag L, Wong G and Costello S. The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study. See http://www.costellomedical.com/wp-content/uploads/2014/03/Madrid_Poster_PHP1521.pdf (last checked 27 October 2014).
19. Department of Health. Pharmaceutical Price Regulation Scheme (PPRS) 2014. See https://www.gov.uk/government/publications/pharmaceutical-price-regulation-scheme-2014 (last checked 27 October 2014).
20. Van de Vooren K,Curto A,Garattini L.Optional copayments on anti-cancer drugs.BMJ. 2013;346:f349-f349